Derseree Archary, PhD, is a Research Associate at CAPRISA and Honorary Lecturer at the School of Laboratory Medicine and Medical Sciences at the University of KwaZulu-Natal. Her main research interests are in defining the immune correlates of protection and risk to HIV-acquisition in the female genital tract. Her particular focus is to understand the transudation dynamics and the functional responses of non-neutralizing antibodies in the female genital tract in both vaccine and PrEP studies. She is a consultant to the HIV Vaccine Trials Network’s Mucosal Immunology Group and is also a mentor and supervisor to post-graduate students currently in the National Research Foundation of South Africa’s Centre of Excellence Training Programme at CAPRISA.
Cheryl Baxter, PhD, is a Research Associate and Scientific Writer at CAPRISA and Honorary Lecturer in the School of Nursing and Public Health at the University of KwaZulu-Natal. Her main research interests are in HIV prevention, particularly strategies to reduce HIV acquisition among young women, and issues related to women’s sexual and reproductive health. She has extensive experience in the operations of clinical trials and regulatory compliance and was part of the team implementing the CAPRISA 004 tenofovir gel trial, which provided proof-of-concept that antiretroviral drugs can prevent sexually transmitted HIV infection and herpes simplex virus type 2 in women.
Dr Nigel Garrett, MBBS, MRCP, MSc, DipGUM, DipHIV, DFSRH is the Head of HIV Pathogenesis and Vaccine Research at CAPRISA. As Project Director of the CAPRISA 002 Acute HIV Infection study he is involved in important pathogenesis research such as elucidating mechanisms of the development of broadly neutralizing antibodies in collaboration with CAPRISA’s research partners at the University of Cape Town, the National Institute of Communicable Diseases and the Ragon Institute, Harvard University. He is a specialist physician in HIV and Sexual Health Medicine and has contributed as Principal and Co-investigator to more than 15 randomized clinical trials and large cohort studies. At the Nelson R Mandela School of Medicine, University of KwaZulu-Natal he works as Clinical Lecturer at the Department of Infectious Diseases. He has published on a range of clinical topics in the field of HIV and Sexual Health including HIV resistance, viral load dynamics and assays, point of care testing, new antiretroviral agents, TB screening and HIV disease progression. Currently, he acts as PI on the APPROACH mosaic HIV vaccine study and as Chair on the HVTN 108 Phase 1/2a study. Previously, he has served on the steering committee of the UK Collaborative HIV Cohort Study, was awarded the Health Protection Agency HIV Fellowship Award and gained experience in infectious disease epidemiology at the London School of Hygiene and Tropical Medicine.
Tanuja N Gengiah, B.Pharm, MClinPharm, MS (Epi), PhD is a research pharmacist heading the pharmacy support core since 2003 at the Center for the AIDS Programme of Research in South Africa (CAPRISA). She has substantial experience in commissioning and managing research pharmacies, developing clinical trial protocols and investigational product management in phase II and III HIV treatment, HIV prevention, microbicide and vaccine trials clinical trials.
Her research interests include measuring adherence in HIV treatment and prevention, the study of microbicides for the prevention of HIV and understanding the clinical pharmacology of HIV/TB treatment integration with a particular focus on drug interactions and pharmacokinetics. She was instrumental in the development of innovative technology for measuring adherence in a microbicide trial. Her PhD focused on investigating ART and TB drug interactions during co-treatment with a focus on pharmacogenetic variation due to single nucleotide polymorphisms in drug metabolising enzymes in African patients. She has authored several publications on integrating TB and HIV treatment and on microbicides as an effective HIV prevention strategy.
She is an honorary research fellow with the Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal and a member of the Primary Health Care Expert review committee of the National Essential Medicines List committee with the South African Ministry of Health.
Dr Pamela P. Gumbi, PhD (Medical Virology) is a Scientist at Centre for the AIDS Program of Research in South Africa (CAPRISA). Her work focuses on HIV prevention in young and adolescent women. She is a project Director for CAPRISA 084 and CAPRISA 082 pre-exposure prophylaxis (PrEP) demonstration projects. Her research has focused on studying mucosal immunology of the female reproductive tract (adaptive and innate immunity) in HIV infected, exposed uninfected women and HIV uninfected women. She has more than 10 years of postgraduate research training and experience in health sciences, specifically mucosal HIV immunology in young women.
The studies that she has been involved in have provided insights into the risk factors for HIV acquisition and transmission in young women. Her most cited article showed that if women are infected with HIV, and have high levels of inflammation in their genital tracts, they are likely to shed high levels of HIV virus. This study showed the important role of inflammation in HIV pathogenesis, and that inflammation is a risk factor for HIV transmission. Some of her other work also showed that women who had high levels of inflammation were likely to have to have high numbers of cervical mononuclear cells, including CD4+ T cells, suggesting that inflammation is a risk factor for HIV susceptibility and acquisition. She was awarded SA Fogarty AIDS Training Programme Scholarship. She currently supervises post-graduate students and is a CAPRISA Scientific Review Committee member.
Hilton Humphries (MA, PhD candidate) is a South African Behavioural Scientist working in the field of HIV prevention. He is currently a Scientist at the CAPRISA Vulindlela Research Site. His interests include understanding risk pathways and epidemiological risk in adolescents. He has been involved in the management of large clinical trials, adolescent cash transfer trials, socio-behavioural research, and implementation, qualitative and programmatic research.
He is currently completing his PhD, which aims to understand the ecological and geospatial factors contributing to adolescent HV risk and how these can inform the development of targeted Adolescent HIV prevention interventions. He is a member of the University of KwaZulu-Natal’s Biomedical Ethics Committee and is part of the HIV Prevention trials Network (HPTN) Adolescent working group.
Professor Ayesha Kharsany is a Senior Scientist and epidemiologist at CAPRISA. Her area of expertise is on understanding the evolving HIV epidemic in South Africa and factors influencing HIV acquisition, especially in young women. She is the Principle investigator on two major studies. The first is the HIV Incidence Provincial Surveillance System (HIPSS) study and the second is a study on HIV Transmission Networks, which looks at why young women are at high risk for HIV, transmission dynamics and to identify the source of their HIV infection. Her research focus includes sexually transmitted and lower genital tract infections (STIs), more importantly on bacterial vaginosis, and the role of these infections in facilitating and enhancing HIV transmission. Kharsany has been a co-investigator for the CAPRISA 004 Tenofovir gel trial and the CAPRISA 007 RHIVA trial.
Dr. Lenine Liebenberg, Ph.D. is a Research Associate at the CAPRISA Mucosal Immunology Laboratory, and National Research Foundation RCA Fellow. Dr Liebenberg’s combined academic training in medical virology, microbiology, genetics, and immunology direct the scope of her research in understanding immune responses at the human genital mucosa. She has documented methods to improve genital cell isolation from men and women, methods to facilitate genital cellular immune responses in multicentre studies, and has characterised genital and systemic immune parameters facilitating HIV infection, viral shedding and HIV transmission. Her current interests centre on investigating cytokine and cellular biomarkers of genital immune activation and inflammation, their various causes and the consequences to the risk of HIV acquisition and transmission.
Dr Leila E Mansoor, PhD. is a Senior Scientist at CAPRISA and has over 10 years of extensive clinical trial experience, ranging from proof of concept clinical trials through to post-trial access studies and demonstration projects.
She has undertaken pivotal research in evaluating HIV prevention biotechnologies for young women, with a focus on microbicides, including the development and implementation of novel approaches to adherence support particularly for low literacy level and research naïve populations. Her research focus includes HIV prevention clinical research, microbicides, adherence support and measures in clinical trials, as well as social science research focusing on patient’s knowledge about, attitude to and perceptions of their medicine and disease state.
Dr Kathy Mngadi, MBChB, MPhil, Dip Epi, Dip Clin Trials, Dip HIV Man SA, is a South African clinician involved in HIV prevention research for 12 years. She is a Project Director / Senior Scientist at CAPRISA, and serves as an honorary lecturer for the School of Laboratory Medicine at the Nelson Mandela School of Medicine, University of KwaZulu Natal.
She is the Principal Investigator for HIV Vaccine Trial Network trials, a voting member of the Scientific Governance Committee, a member of the Efficacy Working Group and the Protocol Review Committee, and a protocol co-chair for several studies.
Sinaye Ngcapu, PhD, is a basic scientist in the HIV Mucosal Immunology Laboratory at the Center for the AIDS Programme of Research (CAPRISA). He is also an honorary lecturer in the Department of Medical Microbiology at the University of KwaZulu-Natal. His research interests are centered on studying the role of the commensal microflora at the female genital tract in modulating immune response, with HIV as the primary outcome, and susceptibility to other STIs as a secondary analysis.
Natasha Samsunder, MT, BTech (Quality) is a South African medical technologist who is qualified in clinical pathology and has over 21 years of experience managing clinical laboratories. As the Head of the CAPRISA Laboratories she is tasked with managing and directing the CAPRISA laboratory’s capabilities, quality and research agenda, ensuring that the laboratory functions optimally and that quality of testing performed in the laboratory is of the highest level. She oversees all aspects of laboratory including the site laboratories and collaborating laboratrories. She is a qualified auditor and assists many laboratories to set up and maintain their quality management system in line with ISO standards and Good clinical laboratory practices guidelines.
She is a voting member of the ACTG/IMPAACT Laboratory Technologist Committee and also works closely with all network laboratory centers and research partners to further the research agenda in the field of HIV, TB and STIs.
Jerome Amir Singh (BA, LLB, LLM, MHSc, PhD) is Head of Ethics and Law at CAPRISA. He is the Principal Investigator / Director of the Ethical, Legal, Social, and Cultural Issues (ELSCI) Program on Synthetic Biology, funded by the Bill and Melinda Gates Foundation. He is also Adjunct Professor in the Dalla Lana School of Public Health at the University of Toronto, Toronto, Canada. He serves as an ad hoc Consultant to several UN entities, including the WHO, UNAIDS, UNICEF, TDR, and UNICRI. He is the Co-Chairperson of the HIV Prevention Trial Network’s (HPTN) Ethics Working Group, and a member of the HIV Vaccine Trial Network’s (HVTN) Efficacy Trial Working Group. He is a member of the South African National AIDS Council (SANAC) Technical Task Team on Ensuring Protection of Human Rights and Improving Access to Justice and serves on the Advisory Committee of the Critical Path for TB Regimens (CPTR). He currently serves on several oversight bodies, including the International Ethics Review Board of Médecins Sans Frontières (MSF). He is an elected Founding Member, and two-term Co-Chair of the South African Young Academy of Science (SAYAS), and currently serves as an Academic Editor for PLOS One.
Nonhlanhla Yende-Zuma MSc, is a senior Biostatistician at the Centre for the AIDS Programme of Research in South Africa and a PhD candidate from the University of KwaZulu-Natal. She has substantial statistical expertise in HIV and TB research and was integrally involved in the landmark CAPRISA 004 microbicide gel trial and CAPRISA 003 SAPiT trial. To date, she has co-authored and carried out data analyses for over 20 peer-reviewed journal articles.
Dan Barouch, M.D., Ph.D., is director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. He is also a professor of medicine at Harvard Medical School. In addition, he is a key part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery, the National Institutes of Health Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, and the Ragon Institute of MGH, MIT, and Harvard.
Dr. Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School.
His laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. His laboratory has explored a series of novel vaccine technologies, including adjuvanted DNA vaccines, poxvirus vectors, and alternative serotype adenovirus vectors in both preclinical and clinical studies. In particular, he has advanced a series of novel adenovirus vector-based HIV-1 vaccine candidates from concept and design to preclinical testing to phase 1 clinical trials that are currently underway in both the U.S. and sub-Saharan Africa.
Dr. Barouch is board certified in internal medicine and infectious diseases, and he is committed to mentoring students, clinical fellows, research fellows, and junior faculty and to providing clinical care to patients with infectious diseases.
Professor Hoosen (Jerry) Coovadia is currently a Director at MatCH Health Systems (Maternal, Adolescent and Child Health). MatCH Health Systems with PEPFAR funding (through USAID) supports the KZN Department of Health in their provision of HIV, TB and related diseases treatment, prevention and care services in the eThekwini and uMkhanaykude districts.
Jerry is also the the Chairperson of the Board of the KZN Children’s Hospital Trust and a Commissioner for the National Planning Commission for the Presidency of the Republic of South Africa. He also holds the title of Emeritus Professor of Paediatrics and Child Health and Emeritus Victor Daitz Professor of HIV/Aids Research at the University of KwaZulu-Natal. He was the Scientific Director at the Doris Duke Medical Research Centre at the University of Natal and the Director of BioMed HIV/AIDS Research at the Nelson Mandela School of Medicine. He also held the International Vice-Chair of the Paediatric AIDS Clinical Trials Group (IMPAACT), the Deputy Chair of Transitional National Development Trust, Co-Chair of the Advisory Board to the Artists for a New South Africa's Amandla AIDS Fund and Member of the South African Academy of Science. He has also been a member of a number of UN Committees.
He holds Honorary Doctorates from the Universities of Cape Town, Kwa-Zulu Natal and the, Witwatersrand. A Master of Science from the University of Birmingham, UK. A FCP from the College of Medicine of South Africa and a Bachelor of Medicine & Bachelor of Surgery from the University of Bombay, India.
He has published more than 338 papers on factors causing morbidity, disability and mortality among Africa`s children.
He has received a number of awards including the Nelson Mandela Award for Health and Human Rights (co-recipient with Judge Edwin Cameron), The Order of the Star of S.A for Contributions to Democracy & Health presented by former President Nelson Mandela, The 2013 Scientific Freedom and Responsibility Award from the American Association for the Advancement of Science (AAAS), The Lifetime Achievement Award from the HIV Congress in India, The Lifetime Achievement Award from the National Research Foundation and most recently the SAMRC President’s Award for Exceptional Contributions to Medical Research.
Amrita Daftary is an Assistant Professor of Research in Epidemiology at McGill University, Canada, and an Investigator at the McGill International TB Centre. She uses qualitative methods to study the social contexts, determinants and impacts of TB and HIV/AIDS in diverse global settings, with particular interest in co-infection and drug-resistant TB. She is devoted to highlighting the patient’s voice in public health research, practice and policymaking. Amrita currently contributes to a number of exploratory as well as mixed-methods interventional projects in sub-Saharan Africa, India and Canada. She has an MPH in Health Promotion from Columbia University, a PhD in Public Health from the University of Toronto, and post doctorate from ICAP at Columbia University. Her primary training was in pharmacy. Amrita holds an adjunct appointment in Social and Behavioral Sciences at the Dalla Lana School of Public Health, University of Toronto.
Dawood works in the CAPRISA Clinical Trials Unit for AIDS/Tuberculosis Prevention and Treatment (CAPRISA CTU). Here she serves as the lead site investigator for HPTN 077, Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected men and women and the HVTN703/HPTN081, Phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralising monoclonal antibody in reducing acquisition of HIV-1 infection at the Vulindledla research site. Dawood is an infectious diseases specialist physician and epidemiologist with 15 years of experience in infectious diseases management. She is also the Head of the Infectious Diseases Unit at Grey’s hospital where she provides tertiary care for those with complicated infectious diseases.
Tulio de Oliveira is a full Professor at Nelson R. Mandela School of Medicine at UKZN and a Research Associate of CAPRISA. He is recognised as an expert on HIV genetic data and bioinformatics software development. He received his PhD at the Nelson R. Mandela School of Medicine in 2003, he was a Marie Curie Fellow at the University of Oxford, U.K. in 2006 and has recently been awarded a Royal Society Newton Advanced Fellowship. In total, he has published over 100 manuscripts, developed dozens of bioinformatics software applications and databases. Currently Prof. de Oliveira's has a research group with 18 researchers and/or post-graduate students, more information about his group research website http://www.bioafrica.net.
Andy Gray B Pharm, MSc (Pharm), FPS, FFIP is a pharmacist whose research interests include policy analysis (in particular, the development and implementation of National Medicines Policies), rational medicines use and the application of antiretroviral therapy in resource-constrained settings. He is a Senior Lecturer in the Division of Pharmacology, Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal. Mr Gray is a Fellow and Honorary Life Member of the Pharmaceutical Society of South Africa, a past President of the South African Association of Hospital and Institutional Pharmacists, a past President of the Hospital Pharmacy Section, past Chairman of the Board of Pharmaceutical Practice and currently a Vice-President and Fellow of the International Pharmaceutical Federation (FIP). He was appointed to the South African National Essential Medicines List Committee in 2013 and to the South African Medicines Control Council in 2015. He has served on the Names and Scheduling Expert Committee of the MCC since 2000 and on its Legal Committee since 2016. He is a Member of the World Health Organization’s Expert Panel on Drug Policies and Management and has served as a member, rapporteur and co-chairperson of the Expert Committee on the Selection and Use of Essential Medicines, as chairperson of the sub-committee on Essential Medicines for Children, and on the WHO Guidelines Review Committee.
Professor Bavesh Kana directs the University of the Witwatersrand (Wits) node of the DST/NRF Centre of Excellence for Biomedical TB Research and is an Associate Professor (Reader) in the Wits Faculty of Health Sciences. He obtained his PhD at Wits and has worked in several US institutions, including the University of Pennsylvania, Texas A&M University, the Public Health Research Institute and Harvard Medical School. He is the recipient of the Friedel Sellschop Research Award, the South African MRC Career Development Award, and was part of the team that received the National Health Laboratory Service Innovation Award. Prof. Kana was also appointed as an Early Career Scientist of the Howard Hughes Medical Institute, he is one of 26 scientists worldwide to receive this accolade. In 2012, he was selected as one of the 200 top young South Africans by the Mail and Guardian newspaper. More recently, Prof. Kana was awarded the first-time inventor’s award and first-time innovator’s award by Wits Enterprise for the creation of novel tuberculosis diagnostic reagents that are currently being marketed in over 30 countries. He has been admitted to the Academy of Science of South Africa and was also selected for the CEO Titan Award, which recognized his outstanding contribution to medical science in South Africa, the SADC region and the African continent.
Dr. Douglas Kwon is a physician scientist and Director of Clinical Operations at the Ragon Institute of MGH, MIT and Harvard. He has a clinical practice in the division of Infectious Diseases at Massachusetts General Hospital. The focus of his current research is understanding the role of mucosal tissues in HIV acquisition and disease progression. His lab is involved in developing and applying new technologies to overcome the technical barriers that have impeded our understanding of mucosal immunity to date. This includes the application of novel techniques and functional assays to assess HIV-specific immune responses and the microbiome at mucosal sites
Dr. Marian Loveday is a scientist in the Health Systems Research Unit of the South African Medical Research Council. She worked at different levels within the health systems of South Africa for many years before moving into research. These included work at a community level training and managing a community health worker and rehabilitation worker programme; work as a district health manager; and as a district facilitator assisting districts most in need of improving their primary health care services, including the TB programme. She then moved into research focusing on health systems research through the lens of TB, drug resistant TB and HIV. Although she is now in a research post, she continues to work closely with different levels of the department of health assisting with policy development, evaluation and service implementation.
During the last five years Dr. Loveday was instrumental in drawing up the policy on decentralisation and deinstitutionalisation for patients with MDR-TB and for evaluating the effectiveness of different models of care for MDR-TB patients, and has contributed to international debates in this regard. Her research has highlighted the impact of health service performance on patient adherence to treatment and treatment outcomes as well as highlighting patient experiences and the dilemmas and experiences of front-line health care workers. Loveday received her PhD from the University of KwaZulu-Natal, has published over 20 articles and has just been rated as an NRF scientist.
Lindi Masson, PhD is a Researcher in the Division of Medical Virology, Department of Pathology at the University of Cape Town, a National Research Foundation RCA Fellow and affiliate of CAPRISA. She has training in microbiology, genetics, pharmacology, virology and immunology. Dr Masson’s research has shown that women who have inflammation in their genital tracts are at high risk of HIV acquisition and that the main drivers of genital inflammation in South African women are asymptomatic sexually transmitted infections and dysbiotic vaginal microbiota. She has identified three cytokine biomarkers of genital inflammation and asymptomatic infections and is currently developing a point-of-care test to measure these cytokines. Dr Masson is also setting up female genital tract proteomics capacity at UCT and is leading another study aimed at characterising bacterial isolates from the female genital tract to better understand the roles that vaginal bacteria play in HIV acquisition.
Dr Lyle McKinnon is an immunologist with a specific interest in mucosal immune systems. His main research focuses on correlates of HIV acquisition in high-risk populations including young women in sub-Saharan Africa. Examples of ongoing research projects include understanding the role of gut homing receptors, co-infections, injectable contraceptives, female reproductive tract cytokines, the vaginal microbiome, immunogenetics, and interferon pathways as determinants of HIV infection risk. Each of these is studied in the context of exposure to emerging HIV prevention technologies. He is also carrying out work to understand immunological correlates of tuberculosis recurrence in HIV infected individuals receiving antiretroviral therapy.
Koleka Mlisana MBChB, MMed Micro, PhD is currently an Associate Professor and Head of the Department of Medical Microbiology at the Nelson R Mandela School of Medicine and Inkosi Albert Luthuli Hospital Academic Complex of the University of KwaZulu-Natal and the National Health Laboratory Services. Prof Mlisana has been among South Africa’s leading scientists in HIV pathogenesis and prevention research and participated in seminal studies that have revealed how the body responds in acute HIV infection. She is a widely respected researcher and is currently working in the field of Medical Microbiology focusing on sexually transmitted infections and tuberculosis research. With KwaZulu- Natal province as the epicenter for both TB (including DR-TB) and HIV, Prof Mlisana’s group is exploring newer diagnostic and susceptibility testing methods for Mycobacterium tuberculosis, as well as understanding mechanisms of drug resistance. Amongst many other national commitments, she currently seats on the recently established Ministerial Advisory Committee on Antimicrobial Resistance.
Professor Penny Moore, PhD, is a Reader and DST/NRF South African Research Chair of Virus-Host Dynamics at the University of the Witwatersrand and the National Institute for Communicable Diseases, and Research Associate at CAPRISA, University of KwaZulu-Natal. She obtained her MSc in Microbiology at WITS, studying gastroenteritis-associated adenoviruses. This was followed by a PhD in Virology (Medicine) at the University of London (studying the Hepatitis B virus) in 2003 before returning to South Africa to join NICD/WITS. Her current research focuses on HIV broadly neutralising antibodies and their interplay with the evolving virus. Moore currently supervises 7 PhD students and is funded through the South African Medical Research Council, the National Research Foundation/Department of Science and Technology and the NIH.
Professor Lynn Morris, DPhil, heads the HIV Virology Section at the National Institute for Communicable Diseases and holds a joint appointment as Research Professor at the University of the Witwatersrand, where she also completed her undergraduate studies. For the past 24 years she has been researching the virological and immunological aspects of South African HIV-1 subtype C infection, making significant contributions to our understanding of how the HIV antibody response develops. HIV vaccine development is now a major focus of her research and she is responsible for performing neutralising antibody assays on human clinical trials conducted in South Africa.
Morris received her DPhil from the University of Oxford, whereafter she completed a post-doctoral fellowship at The Walter and Eliza Hall Institute of Medical Research in Australia before returning to South Africa. She has supervised 30 PhD and MSc students and has published over 200 papers in peer-reviewed Journals, holding a current author H-Index of 51. She an NRF A-rated Scientist and is internationally recognised. She received several awards for her contribution to HIV vaccine research and recent awards include the University of the Witwatersrand’s Vice Chancellor Research Award (2014) and the South African Medical Research Council’s Gold Merit Award (2015). She is also listed on the Thompsons Reuters 2015 and 2016 ISI list of the 3000 highest cited researchers in the world
Vivek Naranbhai, MBChB (UKZN), BSc.Hons (Medical Microbiology, UKZN), PhD (UKZN), DPhil (Oxon).
Vivek Naranbhai is a South African clinician-scientist a research associate of CAPRISA, and a previous deputy director of the CAPRISA Vaccine and Pathogenesis program. He is currently a Research Fellow at the Ragon Institute of MGH, MIT and Harvard, a Research Fellow at Harvard Medical School and a Clinical Research Fellow at the Wellcome Trust Centre for Human Genetics, University of Oxford. He moved to Oxford in 2011 as a Rhodes Scholar (Keble and KwaZulu Natal 2011) and to Boston in 2016.
Vivek’s work spans immunology, genetic epidemiology and bioinformatics in a range of infectious diseases, chiefly HIV and tuberculosis – the world’s leading killers of adults and adolescents. He co-leads the International Tuberculosis Host Genetics Consortium, a global effort to understand how the genetic background of humans affects our risk of tuberculosis.
Click here for publications and here for Vivek’s profile.
Assistant Professor of Medicine and Epidemiology at Columbia University Medical Center
Dr. O'Donnell's research interests are in tuberculosis (TB), HIV, and global health, including ethical issues in global health research. Current research is centered in South Africa and involves collaboration with the KwaZulu-Natal Research Institute on TB/HIV (K-RITH), and the Centre for AIDS Programme of Research in South Africa (CAPRISA) and the Jacobs' lab at Albert Einstein College of Medicine.
Drug-resistant tuberculosis is an important global public health concern because of increasing incidence, low cure rates, and high reported mortality. Nowhere has this increased incidence generated more concern than in South Africa where interactions between TB and generalized HIV/AIDS epidemics are causing explosive increases in TB incidence and TB case-fatality rates. The most drug-resistant form of tuberculosis, extensively drug resistant tuberculosis (XDR-TB), is increasingly prevalent in South Africa.
Dr. Christina Thobakgale-Tshabalala is a Senior Lecturer and Researcher at the HIV Pathogenesis Program (HPP) at the University of KwaZulu-Natal (UKZN). She obtained her junior degrees from University of the North, a PhD from UKZN, followed by a Postdoctoral Fellowship with UKZN and the Ragon Institute at Harvard University. Past research interests include understanding cellular and viral factors that influence disease progression in HIV-infected infants. Currently, her research focuses on innate immune responses, particularly factors that predispose individuals to disease severity and their impact on HIV and TB pathogenesis. She has authored and co-authored 24 publications in internationally recognised peer-reviewed journals. She has a keen interest in the discovery and development of young researchers. She currently lectures undergraduate and postgraduate students and supervises postgraduate students, mostly at Masters and PhD level.
Professor Carolyn Williamson, PhD, is a Research Affiliate of CAPRISA and was instrumental in establishing the CAPRISA 002 acute infection study. She is a molecular virologist with a research interest in preventing HIV infection through passive and active immunisation. She is known for her work on elucidation of properties of transmitted viruses, the interplay between host immunity and viral evolution, and pathogenesis. More recently she has become involved in working towards a cure. She is located at the University of Cape Town where she is Head of Division of Medical Virology, Department of Pathology; a full member of the Institute of Infectious Disease and Molecular Medicine; and a member of the Wellcome Centre for Infectious Diseases Research in Africa.
CAPRISA was created in 2001 and formally established in 2002 under the NIH-funded Comprehensive International Program of Research on AIDS (CIPRA) by five partner institutions; University of KwaZulu-Natal, University of Cape Town, University of Western Cape, National Institute for Communicable Diseases, and Columbia University in New York. CAPRISA is a designated UNAIDS Collaborating Centre for HIV Prevention Research. The main goal of CAPRISA is to undertake globally relevant and locally responsive research that contributes to understanding HIV pathogenesis, prevention and epidemiology as well as the links between tuberculosis and AIDS care.